Turbine

25/08/2026

Big news: Turbine has been nominated again for the Prix Galien USA Award in the Best Startup category 🏅

Often referred to as the "Nobel Prize for biopharma innovation," the Prix Galien has spent two decades recognizing the people and companies pushing biomedical science forward. Being named among this year's nominees is a meaningful nod to what our team has built: a platform that virtualizes practical biological assays, so drug discovery moves faster and with a higher probability of success.

vLab™ exists because Turbiners built it. Our partners chose to reimagine drug discovery alongside us. This nomination belongs as much to them as to us.

We'll be cheering on the full class of nominees at the awards ceremony on October 29 at the American Museum of Natural History in New York City.

Congratulations to all companies who also made the shortlist! See the full list here:
https://eu1.hubs.ly/H0xQYWP0

25/08/2026

The Virtual Biology Meetup is back for round three, and this episode gets real about R&D.

We're picking up a question that keeps coming up in R&D: predictions are one thing, but do these tools actually hold up when real decisions are on the line? From scaling Perturb-seq to a fireside on what it actually takes to adopt virtual biology inside a pharma organization, this one goes past the hype and into practice.

Joining the conversation:
🔹 Ci Chu, PhD (Xaira Therapeutics)
🔹 Vinay Varadan, PhD (Merck)
🔹 Krishna Bulusu, PhD (Turbine)
Moderated by Daniel Veres, MD, PhD, Co-founder & CSO at Turbine.

📅 September 15, 2026 | 5:00-6:30 PM CET
The meetup is going to be broadcast, sign up here: https://eu1.hubs.ly/H0xQBzb0

See you there!

Drug developers don't run on predictions alone, they run on decisions. In this episode, we shift the lens from building models that predict specific outcomes…

19/08/2026

The first episode of our upcoming series with The AI in Business Podcast is live.🎙️

Kristóf Szalay (CTO & Co-Founder) and Gerold Csendes (Staff Machine Learning Scientist) sat down with Marilie Fouché to unpack a question the industry still hasn't answered clearly: when is a virtual cell model actually reliable enough to guide a real R&D decision?

Building on our whitepaper Assessing a Virtual Cell's Utility, the conversation explores topics from the state of benchmarking across the field to specific cases where we already see that small, targeted datasets beat a bigger, monolithic data.

🎧 Listen to the full episode: https://eu1.hubs.ly/H0xKrq80
📚 Read our whitepaper: https://eu1.hubs.ly/H0xKrtX0

Thank you Marilie Fouché and the EmerJ team for a great conversation!
Watch out for three more episodes in this series.

12/08/2026

Two Krishnas. One podcast. Zero small talk.🎙️
Our VP Krishna Bulusu joined Krishna Chandra Eluri on Norstella's Proof of Concept to talk AI in drug discovery.

In a field moving this fast, Pharma x TechBio partnerships are becoming the real competitive advantage. They de-risk innovation, speed up adoption, and help teams make better-informed decisions earlier.

That's also the value behind our vLab™ and Virtual Assays: they bring predictive experimentation at computational scale into existing pharma workflows, so teams can explore more biology and build confidence in the calls that matter before committing time and resources in the wet lab.

Worth a listen. 👇🏻

In Vivo Podcasts · Episode

07/07/2026

Next week Bence Czakó, Milán Sztilkovics and Matteo Tardelli will be at ISMB in Washington, DC, between July 12–16. 🗺️

Bence and Milán will present a poster on SCAPE: Sampling-Calibrated Adjustment of Perturbation Effects. SCAPE is Turbine’s Perturb-seq normalization method for correcting perturbation effect sizes, helping to make perturbation data more reliable and comparable across experimental contexts.

The method is already being used across several in-house projects, so if you are attending ISMB, it is definitely worth stopping by to hear more about the details. We are very excited to bring SCAPE to the broader computational biology community.

Presentation details
📅 July 15 | 15:35 ET during the MLCSB session
📍International Ballroom Center, Washington Hilton

In case you cannot make it, you can also find us in the Poster Hall (Columbia), during the poster sessions between 10:00–11:00 and 16:00–16:40 ET with Poster C-401.

We would love to see you there and walk you through SCAPE in more depth or simply have a chat. 👋 ☕

25/06/2026

Resources like DepMap and Open Targets have transformed how researchers can uncover cancer vulnerabilities in early discovery. The next frontier is turning those insights into stronger, clinically more relevant decisions: which targets to prioritize, which patient cohorts to position for, and what hurdles to expect emerging in translation.

This article discusses how Virtual Assays can augment existing discovery toolkits by enabling rapid assessment and ranking of key hypotheses, and de-risking decisions through a mechanistic understanding of target biology.

Read the full article to learn more through practical examples.

New tools are building on DepMap's foundations to help innovative companies identify hidden clinical positioning opportunities in competitive spaces.

24/06/2026

A few weeks back, Csilla Hegedüs and Krishna Bulusu held a webinar on new possibilities that Virtual Assays open for early discovery.

Using Turbine’s Virtual Lab, Csilla and Krishna showed how millions of simulated experiments can help uncover hidden dependencies, synthetic lethal pairs, and mechanistic insights to not only accelerate early discovery workflows, but also help rank and de-risk target candidates.

Thank you to everyone who joined us live and contributed to the conversation!

In case you missed it, watch the recording and share your thoughts with us! 👀

While foundational resources like DepMap and Open Targets have acce...

23/06/2026

The race is over, but this event was never just about the finish line. 🏃🏻‍♂️

This year, we once again took on Brutál Futás in support of Démétér Alapítvány, whose house helps families stay together while children undergo long and difficult medical treatments. Every donation helps create comfort, stability, and hope for families who need it most.

A huge thank you to everyone who supported, encouraged, and helped our case. If you’d still like to contribute, the fundraise remains open until July 15: https://eu1.hubs.ly/H0wpdRG0

18/06/2026

Mud? Check.

Obstacles? Check.

Team spirit? Absolutely.

The course was tough, but we passed Brutál Futás with flying horrors. A huge congratulations to everyone who took part and represented Turbine out on the course. 🏃🏻‍♀️

And while the race is behind us, the reason we run remains just as important.

If you’d like to support Démétér Alapítvány, donations are open until July 15: https://eu1.hubs.ly/H0wgjyf0

17/06/2026

Neeraj Rao, Pier Giorgio Pacifici, and Richard Izrael will be attending BIO in San Diego from June 22–25. 🌴

Come chat with us about Virtual Assays, and how the Virtual Lab helps pharma teams make faster, more confident decisions for R&D.

In case you’ll be attending in person, come say hi at Booth 3822 👋.